Acute Myocardial Infarction, Carotid Atherosclerosis, Severe Periodontitis
Conditions
Keywords
Acute Myocardial Infarction, Severe Periodontitis, FDG-PET, Carotid Atherosclerosis
Brief summary
Multicenter randomized clinical trial with two arms in patients hospitalized for an AMI nested in the Frenchie registry. Periodontal therapy is performed by periodontists in the intervention group versus treatment by dental surgeons as part of their usual practice in the control group. For the intervention group, periodontal management will be carried out for a maximum of 6 months after randomisation, prolonged by a follow-up of 6 months including a maintenance visit at M9. All patients will have an FDG-PET at M0 and M12 for evaluation of inflammation on carotid atherosclerotic plaques.
Detailed description
Eligible adults 30 to 70 years old hospitalized for an MI, (cf inclusion and non-inclusion criteria), will be asked to participate in the study. (screening) At M0 : * patients will be examined by a periodontist for assessing the severity of periodontitis (standard oral examination including a periodontal screening test). * Patients with severe periodontitis will then receive: Complete periodontal examination of all teeth (6 sites per tooth) including pocket depth measurement, measurement of gingival recession, plaque index, gingival bleeding index, and a gingival fluid sample. Patients will then be informed of their periodontal status and therapeutic options. At this point, the patient may decide not to follow the treatment and will not be randomized. * Patients who agree to continue the study will have a venous blood sample and a PET-FDG examination. Patients in whom the acquisition of FDG-PET is impossible will not be randomized. At the end of these examinations, if all the conditions are met, the randomization will be carried out : * Intervention group: Periodontal treatment, for a maximum of 6 months. At the end of the periodontal treatment, a follow-up of at least 6 months, including a maintenance visit to M9, will be performed. * Control group: patients will be referred to their treating dentist for usual care. At M12 (+12 months) : All patients (intervention group and control group) will have the same tests as M0
Interventions
OTHERPeriodontal treatment
Periodontal treatment can last up to 6 months depending on the periodontal state, followed by a follow-up period of at least 6 months including a visit to M9. Briefly, the intervention group includes initial therapy in 48 hours maximum which includes information on oral hygiene techniques (verbal + brochure), scaling and surfacing of dental roots with antiseptic irrigation and non-tooth extraction. retainable. This initial therapy is followed by a resumption of periodontal clinical measures after 6 weeks. Depending on the degree of improvement of the measurements, the treatment is either completed, or continues with further scaling-surfacing and / or performing one or more periodontal surgeries. Periodontal monitoring period often called maintenance includes repeated sessions of simple scaling whose rate does not exceed 4 per year.
Sponsors
National Research Agency, France
Assistance Publique - Hôpitaux de Paris
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients hospitalized for an acute myocardial infarction and included in the Frenchie registry * Score ≥ 5 on the screening questionnaire for periodontitis * Six teeth at least (excluding wisdom teeth) * Consent signature * Affiliation to a French medical insurance (Sécurité Sociale)
Exclusion criteria
* Patients with diseases,other than cardiovascular and diabetes, known to change the periodontal state such as AIDS, rheumatoid arthritis, Chediak-Higashi syndrome, Papillon-Lefèvre * Systemic antibiotic therapy\> 48 hours in the 3 months prior to inclusion * Acute heart failure * Uncontrolled ventricular rhythm disorders * Impossibility for the patient to attend follow-up visits * Impossibility to maintain the extended position for 20 minutes * Immunosuppressive therapy\> 1 month in the 6 months prior to inclusion * Pregnancy, breastfeeding * Known hypersensitivity to chlorhexidine, povidone, 18-fluoro-deoxyglucose
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effect of treatment of severe periodontitis in patients with an AMI | 12 months (+12months) after randomization | The primary endpoint will be the absolute difference of the Most-Diseased Segment (MDS) -Target to Background Ratio (TBR) measured at the segment with the highest activity on carotid arteries between the initial PET scan and the PET scan performed at 12 months (+12months) after randomization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Impact of periodontitis treatment on the intensity of global inflammatory activity measured in the alveolar bone | 12 months (+12months) after randomization | Relative ((M12-M0)/M0) and absolute (M12-M0) differences of TBR in the alveolar bone |
| Impact of periodontitis treatment on the intensity of global inflammatory activity measured in the thoracic aorta | 12 months (+12months) after randomization | Relative ((M12-M0)/M0) and absolute (M12-M0) differences of mean TBR in the thoracic aorta |
| Dysbiosis | 12 months (+12months) after randomization | Changes in the dysbiosis index |
| Effect of treatment of severe periodontitis in patients with an AMI | 12 months (+12months) after randomization | Relative difference of the most-diseased segment (MDS) Tissue to Background ratio (TBR) ((M12-M0)/M0) of the Most-Diseased Segment (MDS) -Target to Background Ratio (TBR) measured at the segment with the highest activity |
| Inflammatory markers concentrations in the gingival fluid and in the plasma | 12 months (+12months) after randomization | Changes in the inflammatory markers including IL-1β, IL-6, IL-8, TNFalpha, MMP8, MMP9 concentrations in the gingival fluid and in the plasma |
| Evaluation of overall inflammation in vascular arteries | At randomization | Correlation between soluble CD31 / cleaved CD31 ratio and TBR |
| Evaluation of TBR measurments according to glycemia values | 12 months (+12months) after randomization | Evaluation of TBR measurments according to glycemia values measured prior to FDG-PET |
| CD31 in plasma and gingival fluid | 12 months (+12months) after randomization | Changes in concentrations of soluble CD31 in plasma and the gingival fluid |
Countries
France
Contacts
Primary ContactPhilippe Gabriel STEG
Outcome results
None listed